The problem being cited is something that the FAA and Boeing have been looking into since 2000, and the planes have already been subject to earlier inspections.
But the FAA, in a notice in the Federal Register on Monday, said it has determined that potential problems with rivets could cause "failures or jams" that affect the plane's ability to climb or descend. The failure could result in "possible loss of control of the airplane," the FAA said.
The problem has not been cited as a cause in any crash of a 767, which is one of the most widely-used Boeing jets. Boeing has delivered 1,061 of the long-range, widebody planes since it went into service in 1982.
Some of the airlines objected to the proposed FAA action. United Continental (UAL, Fortune 500) filed comments arguing that previous inspections ordered by the FAA, along with service bulletins from Boeing, have addressed the risks being cited by the FAA in its new order. But the FAA rejected that argument.
Top Managed Healthcare Companies To Buy For 2015: Gentium SpA(GENT)
Gentium S.p.A., a biopharmaceutical company, focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. It develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. The company has completed a Phase III clinical trial of defibrotide for the treatment of severe VOD in the United States, Canada, and Israel; and a Phase II/III pediatric trial in Europe for the prevention of VOD. It also offers sulglicotide that is developed from swine duodenum, and has ulcer healing and gastrointestinal protective properties in South Korea; and urokinase, which is made from human urine to treat various vascular disorders, such as deep vein thrombosis and pulmonary embolisms. The company was formerly known as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in July 2001. Gentium S.p.A. was founded in 1993 and is headquartered in Villa Guardia, Italy.
Advisors' Opinion:- [By James Oberweis]
Gentium Spa (GENT) is focused on the development and commercialization of its leading product, defibrotide, to treat certain complications arising from chemotherapy, and bone marrow and stem cell transplantation therapy.
- [By Jake L'Ecuyer]
Shares of Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) got a boost, shooting up 7.77 percent to $123.65 after the company announced its plans to buy Gentium SpA (NASDAQ: GENT) for around $1 billion.
- [By Sean Williams]
A parabolic problem
It has also been a year to remember for shareholders of biopharmaceutical company Gentium (NASDAQ: GENT ) whose share price has catapulted approximately 600% off its lows thanks to growth in its lead drug Defibrotide (known as Defitelio in the European Union).
Hot Healthcare Technology Companies To Buy Right Now: Le Gaga Holdings Limited (GAGA)
Le Gaga Holdings Limited engages in cultivating, processing, and distributing vegetables, fruits, and tea leaves in the People�s Republic of China and Hong Kong. The company is also involved in cultivating and selling fir trees. It offers solanaceous vegetables, including sweet peppers, tomatoes, eggplants, pumpkins, and cucumbers; leafy vegetables comprising flowering Chinese cabbage, baby bok choy, and baby Chinese cabbage; and cruciferous vegetables, such as broccoli and Chinese cabbage. As of March 31, 2012, the company operated 11 farms with an aggregate area of 1,671 hectares in Fujian, Guangdong, and Hebei provinces. It sells approximately 50 varieties of vegetables primarily to wholesalers, institutional customers, and supermarket chains. The company was founded in 2004 and is based in Kowloon, Hong Kong.
Advisors' Opinion:- [By Monica Gerson]
Le Gaga Holdings (NASDAQ: GAGA) is estimated to report its Q4 earnings.
Adobe Systems (NASDAQ: ADBE) is expected to post its Q3 earnings at $0.34 per share on revenue of $1.01 billion.
Hot Healthcare Technology Companies To Buy Right Now: Wetherspoon(jd)
JD Wetherspoon plc owns and operates pubs. The company operates 823 pubs that offer food and drinks in England, northern Ireland, Scotland, and Wales. It also operates hotels. The company was founded in 1979 and is headquartered in Watford, the United Kingdom.
Advisors' Opinion:- [By Matt Egan]
While Nasdaq missed out on Alibaba, it did land a number of high-profile tech IPOs this year, including Weibo (WB), JD.com (JD) and GoPro (GPRO), which zoomed over 30% higher in its debut on Thursday. Nasdaq said 62% of all U.S. IPOs so far this year have occurred on its exchange.
- [By Lisa Levin]
JD.com (NASDAQ: JD) shares declined 4.03% to $28.80 in pre-market trading after the company reported a quarterly net loss of 582.5 million yuan ($93.9 million).
- [By Gillian Tan]
The hiring caps a busy week for Bank of America, which co-led the IPO of�Chinese online retailer JD.com(JD). The stock jumped as much as 20% higher on its debut�Thursday.
- [By Lisa Levin]
JD.com (NASDAQ: JD) dropped 3.35% to $29.00 after the company reported a quarterly net loss of 582.5 million yuan ($93.9 million).
Intercept Pharmaceuticals (NASDAQ: ICPT) shares fell 2.60% to $288.66 after falling 3.66% on Thursday.
Hot Healthcare Technology Companies To Buy Right Now: Alexandria Real Estate Equities Inc. (ARE)
Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry. Its properties consist of buildings containing scientific research and development laboratories, and other improvements. The company offers its properties for lease primarily to universities and independent not-for-profit institutions; and pharmaceutical, biotechnology, medical device, life science product, service, biodefense, and translational research entities, as well as governmental agencies. As of December 31, 2006, it had 159 properties, including 156 properties located in 9 states in the United States and 3 properties located in Canada. As a REIT, the company is not subject to federal income tax to the extent that it distributes 100% of its taxable income to its stockholders. The company was founded in 1993 and is based in Pasadena, California.
Advisors' Opinion:- [By Markus Aarnio]
Owens Realty Mortgage's competitors include American Assets Trust (AAT), Alexandria Real Estate Equities (ARE) and Boston Properties (BXP). American Assets Trust has seen five insider buy transactions and four insider sell transactions this year. American Assets Trust has a dividend yield of 2.78%. Alexandria Real Estate Equities has seen 14 insider sell transactions this year. Alexandria Real Estate Equities has a dividend yield of 4.10%. Boston Properties has seen one insider buy transaction and four insider sell transactions this year. Boston Properties has a dividend yield of 2.43%.
- [By Shauna O'Brien]
Real estate investment trust Alexandria Real Estate Equities Inc (ARE) announced on Tuesday that its board has approved a 4.6% increase to its quarterly dividend.
The firm has raised its dividend from 65 cents to 68 cents per share, or $2.72 annually. The dividend will be paid on October 15 to shareholders of record on September 30. The stock will go ex-dividend on September 26.
Alexandria Real Estate Equities shares were mostly flat during pre-market trading Tuesday. The stock is down 9% YTD.
- [By GuruFocus]
George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated
- [By Bill Stoller]
After a banner 2013, the overall market has had a challenging start to 2014. However, these four companies have been crushing it: Alexander Real Estate (NYSE: ARE ) , BioMed Realty Trust (NYSE: BMR ) , CommonWealth REIT (NYSE: CWH ) , and Sun Communities (NYSE: SUI ) early on in 2014 vs. the S&P 500. Their relative out-performance can also be seen when compared to the Vanguard REIT Index ETF (NYSEMKT: VNQ ) a good yardstick to measure sector performance.
Hot Healthcare Technology Companies To Buy Right Now: Brookfield Residential Properties Inc (BRP)
Brookfield Residential Properties Inc. (Brookfield Residential) is a land developer and homebuilder.The Company entitles and develops land and builds homes for its own communities, as well as sells lots to third-party builders. It operates in three segments in North America: Canada, California and Central and Eastern U.S. Each of the Company�� segments specializes in lot entitlement and development and the construction of single-family and multi-family homes. As of December 31, 2011, Brookfield Residential controlled 108,197 lots. The Company became a public company on March 31, 2011, by combining the former business of Brookfield Homes Corporation (Brookfield Homes) and the residential land and housing division (BPO Residential) of Brookfield Office Properties Inc. into a single residential land and housing company, achieved through a merger and series of related transactions completed on March 31, 2011. Advisors' Opinion:- [By Dimitra DeFotis]
In the homebuidling category:
Weyerhaeuser (WY), the producer of lumber, was up nearly 3%. On Thursday, Citigroup Analyst Anthony Pettinari wrote that Weyerhaeuser could sell its homebuilder unit for between $2.5 billion and $3.5 billion, and interested buyers in the unit, WRECO, could include Lennar�(LEN), Toll Brothers (TOL) and Brookfield Residential Properties (BRP). About 67% of the Weyerhaeuser unit’s roughly 27,000 lots are in California. Citi has a Buy rating on Weyerhauser and a $35 price target. Lennar, the home builder, was�up 2.6%. Masco (MAS), the building materials maker, was�up 2%.� PulteGroup (PHM), the home builder, was�up 2%. DR Horton�(DHI), the home builder, was�up 1.9%.Among real estate trusts:
- [By Garrett Cook]
Brookfield Residential Properties (NYSE: BRP) shares shot up 21.51 percent to $23.10 after Brookfield Asset Management (NYSE: BAM) proposed to acquire around 30% of the company not currently owned for $23 per share.
Hot Healthcare Technology Companies To Buy Right Now: KCG Holdings Inc (KCG)
KCG Holdings, Inc., incorporated on December 26, 2012, is an independent securities firm. The Company offers investors a range of services designed to address trading needs across asset classes, product types and time zones. It has three operating segments: Market Making, Global Execution Services, and Corporate and Other. On July 1, 2013, the Company announced the completion of the merger whereby Knight Capital Group, Inc. (Knight) and GETCO Holding Company, LLC (GETCO) were combined as part of KCG Holdings, Inc., a new holding company.
Market Making
The Company�� Market Making segment principally consists of market making in global equities and listed domestic options. As a market maker, the Company commits capital for trade executions by offering to buy securities from, or sell securities to, institutions and broker-dealers. The Market Making segment primarily includes client, and to a lesser extent, non-client market making activities in which the Company operates as a market maker in equity securities quoted and traded on the Nasdaq Stock Market; the over-the-counter (OTC) market for New York Stock Exchange (NYSE), NYSE Amex Equities (NYSE Amex), NYSE Arca listed securities, and several European exchanges. As a complement to electronic market making, the Company�� cash trading business handles specialized orders and also transacts on the OTC Bulletin Board, marketplaces operated by the OTC Markets Group Inc. and the Alternative Investment Market (AIM) of the London Stock Exchange. The segment also provides trade executions as an equities Designated Market Maker (DMM) on the NYSE and NYSE Amex. The Market Making segment also includes the Company�� option market making business which trades on all domestic electronic exchanges.
Global Execution Services
The Company�� Global Execution Services segment offers access through its electronic agency-based platforms to markets and self-directed trading in equities, options, fixed income, foreign ! exchange and futures. The Global Execution Services segment generally does not act as a principal to transactions that are executed within this segment however, it will commit capital on behalf of clients, as needed, and generally earns commissions for acting as agent between the principals to the trade. Global Execution Services includes equity sales and trading (including exchange traded funds (ETFs)), reverse mortgage origination and securitization and asset management. This segment also facilitates client orders through program, block, and riskless principal trades and provides capital markets services, including equity offerings, as well as private placements. The Global Execution Services segment also includes the futures commission merchant (FCM) business, which consists of certain assets and liabilities that the Company acquired or assumed from the futures division of Penson Financial Services, Inc.
Corporate and Other
The Corporate and Other segment invests in strategic financial services-oriented opportunities, allocates, deploys and monitors all capital, and maintains corporate overhead expenses and all other income and expenses that are not attributable to the other segments. The Corporate and Other segment houses functions that support the Company�� other segments, such as self-clearing services, including stock lending activities.
The Company competes with BGC Partners (BGCP), Chicago Board Options Exchange (CBOE), CME (CME), GFI Group Inc. (GFIG), ICE (ICE), ITG (ITG), Forex Capital Markets (FXCM), MarketAxess (MKTX), National Association of Securities Dealers Automated Quotations (NASDAQ), and NYSE.
Advisors' Opinion:- [By Sam Mamudi]
Knight, which in July joined with Getco LLC to form KCG Holdings Inc. (KCG) after losing more than $460 million because of the error, agreed to settle charges stemming from mistakes made on Aug. 1, 2012, according to a statement today from the U.S. Securities and Exchange Commission. The regulator said Knight violated the SEC�� market access rule, instituted in 2010 to prevent these kinds of trading missteps.
Hot Healthcare Technology Companies To Buy Right Now: Imprimis Pharmaceuticals Inc (IMMY)
Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company�� Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company�� lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.
Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it exerts its localized anti-inflammatory and analgesic effect. Transdel is the Company�� transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.
Advisors' Opinion:- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
No comments:
Post a Comment